N Engl J Med. 1994 Jul 7;331(1):31-8. doi: 10.1056/NEJM199407073310108.


Sotalol is a novel antiarrhythmic agent combining beta-adrenergic-antagonist actions with the ability to increase cardiac repolarization and refractoriness. The drug's electrophysiologic and clinical profile is different from that of conventional beta-receptor antagonists. As compared with other antiarrhythmic agents, sotalol prevents recurrences of arrhythmia in a higher proportion of patients, particularly among those presenting with ventricular tachycardia and aborted sudden cardiac death. The net hemodynamic effect of sotalol is the result of a balance between the depressant effects due to beta-receptor blockade and an action that tends to increase contractility. Although initially marketed in the United States for treatment of life-threatening ventricular arrhythmias, sotalol also has demonstrated efficacy in many patients with supraventricular arrhythmias. As with all drugs that prolong the QT interval, the syndrome of torsade de pointes is a serious potential adverse effect.

Publication types

  • Review

MeSH terms

  • Action Potentials / drug effects
  • Animals
  • Electrocardiography / drug effects
  • Electrophysiology
  • Humans
  • Myocardial Contraction / drug effects
  • Myocardial Infarction / drug therapy
  • Sotalol / adverse effects
  • Sotalol / pharmacokinetics
  • Sotalol / pharmacology
  • Sotalol / therapeutic use*
  • Tachycardia, Supraventricular / drug therapy
  • Tachycardia, Ventricular / drug therapy


  • Sotalol